HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained a $10 price target, as stated by analyst Joseph Pantginis.
June 21, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Lexicon Pharmaceuticals and maintained a $10 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Lexicon Pharmaceuticals' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100